Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

被引:5
|
作者
Yang, Huili [1 ,2 ]
Feng, Lian [1 ,2 ]
Xu, Linyi [1 ,2 ]
Jiang, Dansheng [1 ,2 ]
Zhai, Fenfen [3 ]
Tong, Guangdong [1 ]
Xing, Yufeng [1 ]
机构
[1] Shenzhen Tradit Chinese Med Hosp, Hepatol Dept, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen 518033, Guangdong, Peoples R China
[3] Shenzhen Futian Ctr Chron Dis Control, Shenzhen 518048, Guangdong, Peoples R China
关键词
APOLIPOPROTEIN-B; PPAR-ALPHA; MICROBIOTA; METABOLISM; PROGRESSION; DEFICIENCY; DISORDERS; BACTERIA; RECEPTOR; OBESITY;
D O I
10.1155/2022/4801695
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of SX on high-fat diet-induced NAFLD rats via the gut-liver axis. Hepatic steatosis and integrity of intestinal mucosa in NAFLD rats were assessed by histopathological staining. The level of lipid and inflammation were estimated by enzyme-linked immunosorbent assay. Western Blotting was used to detect apolipoprotein (apo) B48 expression. 16S rRNA analysis was used to measure the changes of gut microbial composition after SX treatment. The expressions of zona occludens 1 protein (ZO-1), occludin, and secretory immunoglobulin A (sIgA) in the colon were detected by immunostaining to investigate the intestinal barrier function. Our study found that SX reduced hepatic steatosis, the levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, and triglyceride and apoB48 expression but increased peroxisome proliferator activated receptor alpha (PPAR alpha) level. Moreover, SX altered the diversity of gut microbiota, upregulating the relative abundance of f_Prevotellaceae, while downregulating f_Bacteroidales_ S24-7, f_Lachnospiraceae, f_Ruminococcaceae, f_Erysipelotrichaceae, and f_Desulfovibrionaceae. By increasing the expression of ZO-1 and occludin and decreasing the level of proinflammatory factors, including sIgA, lipopolysaccharide, tumor necrosis factor-alpha, interleukin-1 beta, monocyte chemotactic protein-1, and transforming growth factor-beta 1, SX improved intestinal mucosal integrity and barrier function. Our study illustrated that the gut-liver axis was a potential way for SX to ameliorate NAFLD, that is, by regulating the expression of PPAR alpha, apoB48, and modulating gut microbiota to protect the intestinal barrier function, and thus alleviate lipid deposition and inflammatory response in the liver.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Gut microbiota in obesity and nonalcoholic fatty liver disease
    Guo, Lina
    Yang, Keyu
    Zhou, Pinyi
    Yong, Wang
    SURGERY IN PRACTICE AND SCIENCE, 2021, 5
  • [42] Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis
    Li, Hang -Yu
    Huang, Si -Yu
    Zhou, Dan -Dan
    Xiong, Ruo-Gu
    Luo, Min
    Saimaiti, Adila
    Han, Mu-Ke
    Gan, Ren-You
    Zhu, Hui-Lian
    Li, Hua-Bin
    JOURNAL OF ADVANCED RESEARCH, 2023, 52 : 59 - 72
  • [43] Role of Gut Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease
    Dai, Xin
    Wang, Bangmao
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2015, 2015
  • [44] The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation
    van Best, Niels
    Jansen, Peter L.
    Rensen, Sander S.
    HEPATOLOGY INTERNATIONAL, 2015, 9 (03) : 406 - 415
  • [45] The Gut Microbiota and Nonalcoholic Fatty Liver Disease
    Quigley, Eamonn M.
    Monsour, Howard P.
    SEMINARS IN LIVER DISEASE, 2015, 35 (03) : 262 - 269
  • [46] Nonalcoholic Fatty Liver Disease and the Gut Microbiome
    Boursier, Jerome
    Diehl, Anna Mae
    CLINICS IN LIVER DISEASE, 2016, 20 (02) : 263 - +
  • [47] Hepatology Snapshot: Role of bile acids in the gut-liver axis
    Schneider, Kai Markus
    Albers, Stefanie
    Trautwein, Christian
    JOURNAL OF HEPATOLOGY, 2018, 68 (05) : 1083 - 1085
  • [48] Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis
    Chen, Xiang
    Liu, Menghan
    Tang, Jun
    Wang, Ning
    Feng, Yibin
    Ma, Haotian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [49] Roles of the inflammasome in the gut-liver axis
    Wang, Junfeng
    Dong, Rui
    Zheng, Shan
    MOLECULAR MEDICINE REPORTS, 2019, 19 (01) : 3 - 14
  • [50] The Beneficial Effects of Natural Extracts and Bioactive Compounds on the Gut-Liver Axis: A Promising Intervention for Alcoholic Liver Disease
    Zhao, Liang
    Wang, Shaoxuan
    Zhang, Nanhai
    Zhou, Jingxuan
    Mehmood, Arshad
    Raka, Rifat Nowshin
    Zhou, Feng
    Zhao, Lei
    ANTIOXIDANTS, 2022, 11 (06)